Fig. 2: Knockdown of WNT11 in cancer cells impairs tumor growth and improves survival via the adaptive immune system in immunocompetent mice.
From: WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis
a–d Overall survival of immunodeficient NCG or immunocompetent C57BL/6 mice bearing liver metastases seeded with MC38 and Panc02 scramble or shWnt11 cancer cells. n = 6 mice per group. e Gross appearance of MC38 scramble and shWnt11 liver metastases. f, g The liver weight and the number of metastases per liver in the MC38 LM mouse model. h Gross appearance of Panc02 scramble and shWnt11 liver metastases. i, j The liver weight and the number of metastases per liver in the Panc02 LM mouse model. k–n Comparison of CD8+ T-cell infiltration in the MC38 (k, l) and Panc02 (m, n) LM mouse model between the scramble and shWnt11 groups. o–r FACS analysis to determine the frequency of GZMB + CD8 + T-cells relative to the total CD8 + T-cell population in MC38 (o, p) and Panc02 (q, r) liver metastases. s–v FACS analysis to determine the frequency of TNFα + CD8 + T-cells relative to the total CD8 + T-cell population in MC38 (s–t) and Panc02 (u, v) liver metastases. a–d Statistics of survival by Kaplan-Meier test (two-tailed). f, g, i, j, l, n, p, r, t, v. Data are presented as the mean ± SD (n = 5 biological replicates). P-values were calculated using a Student’s t test (two-tailed). Source data are provided as a Source Data file.
